CEO Alice Zhang Speaks at 2017 Xconomy Event "What's Hot in Bay Area Biotech"
Alice Zhang speaks about Verge Genomics' A.I.-enabled approaches to drug discovery
December 6, 2017
SAN FRANCISCO — Verge Genomics CEO Alice Zhang gave a spotlight talk at the annual Xconomy event featuring leading Bay Area-based innovators throughout the healthcare spectrum. Zhang discussed Verge's unique approach combining machine learning genomic network analysis with neurobiology to tackle neurodegenerative diseases.
This year's "What's Hot in Bay Area Biotech" event focused on how top researchers, executives, investors, and thought leaders are navigating the political upheaval while staying focused on creating new medicines and treatments, and improving public health.
About Verge Genomics
Verge is a next-generation drug discovery company that is using human genomic data to accelerate the discovery of treatments for neurodegeneration. Founded by scientists from leading neuro-genomics labs, the Verge team is 14 people including 12 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans.